Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 9, Number 1—January 2003

Perspective

Maintaining Fluoroquinolone Class Efficacy: Review of Influencing Factors

W. Michael Scheld*Comments to Author 
Author affiliation: *University of Virginia, School of Medicine, Charlottesville, Virginia, USA

Main Article

Table 3

Mutant prevention concentrations (MPC)a for various fluoroquinolones to Streptococcus pneumoniae and Pseudomonas aeruginosab

Fluoroquinolone Daily dose
(mg) Cmaxc
(mg/L) P. aeruginosa MPC (mg/L) S. pneumoniae MPC (mg/L)
Ciprofloxacin
500 b.i.d.
3.0
2
NRd

750 b.i.d.
3.6
2
NR
Levofloxacin
500 q.d.
5.7
8
8
Moxifloxacin
400 q.d.
4.5
NR
2
Gatifloxacin 400 q.d. 4.2 NR 4

aMPC values are derived from a study of approximately 100 isolates and are considered provisional.
bSee references 47 and 48 for S. pneumoniae and P. aeruginosa, respectively.
cCmax, peak serum concentration of the drug (41–44).
dNR, not reported.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO